化学発光免疫測定法市場：製品別（装置、消耗品）、技術別（化学発光酵素、微粒子化学発光）、サンプル別（血液、尿）、用途別（感染症、癌）、エンドユーザー別 - 2028年までの世界予測

Chemiluminescence Immunoassay Market by Product (Instrument, Consumable), Technology (Chemiluminescence Enzyme, Microparticle Chemiluminescence), Sample (Blood, Urine), Application (Infectious Disease, Oncology), End User - Global Forecast to 2028

化学発光イムノアッセイ市場は、2023年に推定132億米ドルと評価され、予測期間中のCAGRは7.5%で2028年には190億米ドルに達すると予測されている。HIV/AIDS、肝炎、呼吸器感染症、性感染症などの疾患は、効果的な... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年7月5日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	276	233	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

化学発光イムノアッセイ市場は、2023年に推定132億米ドルと評価され、予測期間中のCAGRは7.5%で2028年には190億米ドルに達すると予測されている。HIV/AIDS、肝炎、呼吸器感染症、性感染症などの疾患は、効果的な治療と管理のために正確でタイムリーな診断を必要とする。ケミルミネッセンスイムノアッセイは、こうした感染症の診断やモニタリングに大きな役割を果たしており、この分野の市場成長を牽引している。

"予測期間中、化学発光イムノアッセイ市場のサンプルタイプ別では、血液サンプル分野が最も高い成長率を示すと予測される"
化学発光イムノアッセイ市場は、血液、尿、唾液、その他のサンプルタイプに区分される。ケミルミネッセンスイムノアッセイにおける血液セグメントは、主に献血数の増加によって大きな成長を遂げており、慢性疾患や感染症の罹患率の上昇も血液サンプルセグメントの成長を支えている。WHOによると、2020年には世界中で1億1850万件以上の献血が行われた。WHOは、献血されたすべての血液について、使用前に感染症、特に梅毒、HIV、マラリア、HBV、B型肝炎、C型肝炎の検査を行うことを推奨している。
"予測期間中、化学発光イムノアッセイ市場のアプリケーション別では、腫瘍学検査分野が最も高い成長率を記録すると予測される"
世界の化学発光免疫測定市場は、感染症、内分泌、腫瘍、骨・ミネラル障害、循環器、血液スクリーニング、自己免疫疾患、アレルギー診断、毒物学、新生児スクリーニング、治療薬モニタリング、呼吸器、神経、代謝障害、消化器、その他の用途に二分される。化学発光イムノアッセイ市場では、腫瘍学検査分野が最も高い成長率を示すと予想されている。癌検査に対する需要の急増は、癌の発生率の上昇、癌の早期発見と早期治療の必要性の強調の増加、癌検診対策の強化といった様々な要因によるものである。
「アジア太平洋：最も急成長している地域の化学発光免疫測定法市場"
世界の化学発光免疫測定市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに区分される。アジア太平洋地域は予測期間中に最も高いCAGRを記録すると予測されている。中国やインドなどのアジア太平洋地域の新興国は、大規模な対象人口の存在と相まって、医療インフラの整備に投資している。これらの要因は、この地域で事業を展開する化学発光免疫測定企業に大きな成長機会をもたらすと期待されている。

化学発光イムノアッセイ市場における主要参入企業のプロファイルの内訳：

- 企業タイプ別：ティア1：28%、ティア2：41%、ティア3：31
- 役職別Cレベル：30%、Dレベル：34%、その他：36
- 地域別北米：37%、欧州：28%、アジア太平洋地域：20%、その他の地域：15
この市場の主要プレーヤーは、F.ホフマン・ラ・ロシュ社（スイス）、ダナハー社（スイス）である。(スイス）、Danaher Corporation（米国）、Siemens Healthineers AG（ドイツ）、DiaSorin S.p.A.（イタリア）、Abbott Laboratories（米国）、Shenzhen Mindray Bio-medical Electronics Co.(Ltd.（中国）、シスメックス株式会社（日本）、Diatron（ハンガリー）、Getein Biotech, Inc.（中国）、Werfen（スペイン）、QuidelOrtho Corporation（米国）、EUROIMMUN（ドイツ）、Merck KGaA（ドイツ）、東ソー株式会社（日本）、Trivitron Healthcare（インド）、Abnova Corporation（台湾）、Elabscience（米国）、Maccura Biotechnology Co.(Ltd.（中国）、Autobio Diagnostics Co.(Ltd.（中国）、Jiangsu Zecen Biotech Co., Ltd.（中国）、Rayto Life and Analytical Sciences Co.(中国）、Daan Gene Co.(中国）、DYNEX TECHNOLOGIES, Inc.（米国）、Zybio, Inc.（中国）、Wiener Laboratorios SAIC（アルゼンチン）、Tianjin Era Biology Technology Co.(Ltd.（中国）。
調査範囲
この調査レポートは、化学発光免疫測定法市場を製品別（消耗品、機器）、技術別（化学発光酵素技術（CLEIA）、電気化学発光免疫測定法（ECLI）、微粒子化学発光免疫測定法）、サンプルタイプ別（血液、尿、唾液、その他のサンプルタイプ）、用途別（感染症、内分泌学、腫瘍学、骨・ミネラル疾患、循環器学、血液スクリーニング、自己免疫疾患、アレルギー診断、毒物学、新生児スクリーニング、治療薬モニタリング、呼吸器学、神経学、代謝異常、消化器学、その他のアプリケーション）、エンドユーザー（病院、臨床検査室、製薬・バイオテクノロジー企業、受託研究機関、その他のエンドユーザー）、地域（北米、欧州、アジア太平洋地域、その他の地域）。本レポートでは、化学発光イムノアッセイ市場の成長に影響を与える促進要因、阻害要因、課題、機会などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、ソリューション、サービス、主要戦略、買収、契約、新製品の発売と承認、化学発光免疫測定法市場に関連する最近の動向に関する洞察を提供しています。化学発光イムノアッセイ市場のエコシステムにおける今後の新興企業の競争分析も本レポートでカバーしています。
このレポートを購入する理由
本レポートは、化学発光イムノアッセイ市場全体およびサブセグメントの収益数の最も近い近似値に関する情報を提供することで、同市場の市場リーダー/新規参入者に役立ちます。本レポートは、利害関係者が競争状況を理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、関係者が市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。
本レポートでは、以下のポイントに関する洞察を提供しています：
- 主要推進要因の分析（慢性疾患および感染症の増加、CLIA技術向上の進歩、ポイントオブケア検査（POCT）需要の高まり、バイオテクノロジーおよびバイオ医薬品産業の成長、高齢者人口の増加、個別化医療へのシフト）、化学発光免疫測定法市場の成長に影響を与える阻害要因（CLIAシステムおよび試薬の高コスト、交差反応性および干渉）、機会（新興国における高成長の見込み、共同研究およびパートナーシップ）、課題（不利な償還シナリオ、熟練専門家の不足）。
- 製品開発/イノベーション：化学発光免疫測定法市場における今後の技術、研究開発活動、新製品発売に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、様々な地域における化学発光免疫測定法市場を分析しています。
- 市場の多様化：化学発光免疫測定法市場における新製品＆サービス、未開拓の地域、最近の開発、投資に関する詳細な情報
- 競合評価：F.ホフマン・ラ・ロシュ社（スイス）、ダナハー社（スイス）など主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。(スイス)、Danaher Corporation (米国)、Seimens Healthineers AG (ドイツ)、Abbott Laboratories (米国)、DiaSorin S.p.A.(イタリア)などの化学発光免疫測定市場戦略における主要企業の市場シェア、成長戦略、サービス提供などを詳細に評価。

ページTOPに戻る

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION 33
1.3.2 GEOGRAPHICAL SCOPE 33
1.3.3 YEARS CONSIDERED 34
1.4 CURRENCY CONSIDERED 34
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Key data from secondary sources 38
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 39
2.1.2.2 Key data from primary sources 40
2.1.2.3 Key industry insights 41
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS 41
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 42
2.2 MARKET SIZE ESTIMATION 42
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION 43
FIGURE 6 MARKET ESTIMATION FROM IVD MARKET 44
FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET 44
FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 45
FIGURE 9 TOP-DOWN APPROACH 45
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 10 DATA TRIANGULATION METHODOLOGY 47
2.4 MARKET SHARE ANALYSIS 48
2.5 STUDY ASSUMPTIONS 48
2.6 RESEARCH LIMITATIONS 48
2.7 RISK ASSESSMENT 49
TABLE 1 RISK ASSESSMENT: CHEMILUMINESCENCE IMMUNOASSAY MARKET 49
2.8 GROWTH RATE ASSUMPTIONS 49
2.9 IMPACT OF RECESSION ON CHEMILUMINESCENCE IMMUNOASSAY MARKET 49
3 EXECUTIVE SUMMARY 51
FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION) 51
FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION) 52
FIGURE 13 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION) 53
FIGURE 14 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION) 54
FIGURE 15 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 55
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 56
4 PREMIUM INSIGHTS 57
4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW 57
FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET 57
4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (2022) 58
FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 58
4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 59
FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 59
4.4 CHEMILUMINESCENCE IMMUNOASSAY MARKET: REGIONAL MIX 60
FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD 60
4.5 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS 61
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
5.2.1 DRIVERS 63
5.2.1.1 Increasing incidences of chronic and infectious diseases globally 63
FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL) 63
FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS) 64
5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years 64
5.2.1.3 Growth of biotechnology and biopharmaceutical industries 66
5.2.1.4 Rapid increase in geriatric population globally 67
FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION) 67
5.2.1.5 Shift toward personalized medicines and individualized treatment decisions 68
5.2.2 RESTRAINTS 68
5.2.2.1 High cost of chemiluminescence systems and reagents 68
5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 High growth prospects for players in emerging economies 69
5.2.3.2 Increasing number of collaborations and partnerships 70
5.2.4 CHALLENGES 70
5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems 70
5.2.4.2 Lack of skilled professionals and aging workforce 70
5.3 VALUE CHAIN ANALYSIS 71
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 71
5.4 SUPPLY CHAIN ANALYSIS 72
FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES 72
5.5 PORTER’S FIVE FORCES ANALYSIS 73
TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS 73
5.5.1 DEGREE OF COMPETITION 73
5.5.2 BARGAINING POWER OF SUPPLIERS 73
5.5.3 BARGAINING POWER OF BUYERS 73
5.5.4 THREAT OF SUBSTITUTES 73
5.5.5 THREAT OF NEW ENTRANTS 74
5.6 KEY STAKEHOLDERS AND BUYING CRITERIA 74
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 74
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 74
TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 74
5.6.2 BUYING CRITERIA 75
FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS 75
TABLE 4 KEY BUYING CRITERIA, BY END USER 75
5.7 REGULATORY LANDSCAPE 76
5.7.1 US 76
TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS 76
FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES 77
5.7.2 CANADA 78
FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES 78
5.7.3 EUROPE 78
TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES 78
5.7.4 JAPAN 79
FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES 79
TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS 80
TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 80
5.7.5 CHINA 80
TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 80
5.7.6 INDIA 81
FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES 81
5.7.7 INDONESIA 81
TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 82
5.7.8 RUSSIA 82
TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES 82
5.7.9 SAUDI ARABIA 83
TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 83
5.7.10 MEXICO 83
FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 83
TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 84
5.7.11 BRAZIL 84
FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 85
5.7.12 SOUTH KOREA 85
TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
5.7.13 MIDDLE EAST 85
5.7.14 AFRICA 86
5.8 TECHNOLOGY ANALYSIS 86
TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 86
5.9 TRADE ANALYSIS 87
5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS 87
TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 87
TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION) 87
5.10 ECOSYSTEM MAPPING 88
FIGURE 36 ECOSYSTEM MAPPING OF CHEMILUMINESCENCE IMMUNOASSAY MARKET 88
5.10.1 ROLE IN ECOSYSTEM 88
5.10.2 KEY PLAYERS OPERATING IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 89
5.11 PATENT ANALYSIS 89
5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 90
TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023–2024 90
5.13 PRICING ANALYSIS 91
5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS) 91
TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD) 91
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91
6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT 92
6.1 INTRODUCTION 93
TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 93
6.2 CONSUMABLES 93
6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF CHEMILUMINESCENCE IMMUNOASSAY MARKET DURING STUDY PERIOD 93
TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE 94
TABLE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION) 95
6.3 INSTRUMENTS 95
6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET 95
TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE 96
TABLE 24 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION) 97
7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY 98
7.1 INTRODUCTION 99
TABLE 25 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 99
7.2 CHEMILUMINESCENCE ENZYME 99
7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET 99
TABLE 26 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021–2028 (USD MILLION) 100
7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY 100
7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET 100
TABLE 27 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION) 101
7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY 101
7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET 101
TABLE 28 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION) 102
8 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE 103
8.1 INTRODUCTION 104
TABLE 29 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 104
8.2 BLOOD 104
8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET 104
TABLE 30 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION) 105
8.3 URINE 105
8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET 105
TABLE 31 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION) 106
8.4 SALIVA 106
8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET 106
TABLE 32 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION) 107
8.5 OTHER SAMPLE TYPES 107
TABLE 33 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION) 108
9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION 109
9.1 INTRODUCTION 110
TABLE 34 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
9.2 INFECTIOUS DISEASES 111
9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET 111
TABLE 35 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 111
9.3 ENDOCRINOLOGY 112
9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET 112
TABLE 36 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION) 112
9.4 ONCOLOGY 113
9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET 113
TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 114
TABLE 38 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 114
9.5 CARDIOLOGY 115
9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET 115
TABLE 39 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION) 115
9.6 ALLERGY DIAGNOSTICS 116
9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS 116
TABLE 40 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 116
9.7 BLOOD SCREENING 117
9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET 117
TABLE 41 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION) 117
9.8 AUTOIMMUNE DISORDERS 118
9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET 118
TABLE 42 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION) 119
9.9 BONE & MINERAL DISORDERS 119
9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS 119
TABLE 43 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 120
9.10 TOXICOLOGY 120
9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET 120
TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION) 121
9.11 NEWBORN SCREENING 121
9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL 121
TABLE 45 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION) 122
9.12 THERAPEUTIC DRUG MONITORING 122
9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET 122
TABLE 46 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021–2028 (USD MILLION) 123
9.13 METABOLIC DISORDERS 123
9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 123
FIGURE 37 GLOBAL INCIDENCE OF DIABETES 124
TABLE 47 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 124
9.14 GASTROENTEROLOGY 125
9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET 125
TABLE 48 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR GASTROENTEROLOGY, BY REGION, 2021–2028 (USD MILLION) 125
9.15 NEUROLOGY 126
9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT 126
TABLE 49 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 126
9.16 RESPIRATORY 127
9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET 127
TABLE 50 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR RESPIRATORY, BY REGION, 2021–2028 (USD MILLION) 127
9.17 OTHER APPLICATIONS 128
TABLE 51 CHEMILUMINESCENCE IMMUNOASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 128
10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER 129
10.1 INTRODUCTION 130
TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 130
10.2 HOSPITALS 130
10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET 130
TABLE 53 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 132
10.3 CLINICAL LABORATORIES 132
10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT 132
TABLE 54 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 133
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 134
10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET 134
TABLE 55 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 135
10.5 OTHER END USERS 135
TABLE 56 CHEMILUMINESCENCE IMMUNOASSAY MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 136
11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION 137
11.1 INTRODUCTION 138
TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION) 138
11.2 NORTH AMERICA 139
FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT 140
TABLE 58 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 59 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 141
TABLE 60 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 142
TABLE 61 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 142
TABLE 62 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143
TABLE 63 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 144
11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA 144
11.2.2 US 145
11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period 145
TABLE 64 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 145
TABLE 65 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146
TABLE 66 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 146
TABLE 67 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 68 US: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 148
11.2.3 CANADA 148
11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market 148
TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES 148
TABLE 70 CANADA: MACROECONOMIC INDICATORS 150
TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 150
TABLE 72 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 151
TABLE 73 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 151
TABLE 74 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152
TABLE 75 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 153
11.3 EUROPE 153
TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 77 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 154
TABLE 78 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155
TABLE 79 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 155
TABLE 80 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 156
TABLE 81 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 157
11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE 157
11.3.2 GERMANY 157
11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market 157
TABLE 82 GERMANY: MACROECONOMIC INDICATORS 158
TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159
TABLE 84 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 159
TABLE 85 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 160
TABLE 86 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 87 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 162
11.3.3 FRANCE 162
11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market 162
TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 163
TABLE 89 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 163
TABLE 90 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 164
TABLE 91 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165
TABLE 92 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 166
11.3.4 UK 166
11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market 166
TABLE 93 UK: MACROECONOMIC INDICATORS 167
TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 168
TABLE 95 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 168
TABLE 96 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 169
TABLE 97 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170
TABLE 98 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 171
11.3.5 ITALY 171
11.3.5.1 Growing geriatric population and increasing support for research to drive market 171
TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 172
TABLE 100 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172
TABLE 101 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 173
TABLE 102 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 103 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 175
11.3.6 SPAIN 175
11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market 175
TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 176
TABLE 105 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 176
TABLE 106 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 177
TABLE 107 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178
TABLE 108 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 179
11.3.7 REST OF EUROPE 179
TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 180
TABLE 110 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180
TABLE 111 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 181
TABLE 112 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 182
TABLE 113 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 183
11.4 ASIA PACIFIC 183
FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT 184
TABLE 114 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 115 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 185
TABLE 116 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186
TABLE 117 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 186
TABLE 118 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187
TABLE 119 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 188
11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC 188
11.4.2 JAPAN 188
11.4.2.1 Growing investments in clinical diagnostics research to drive market 188
TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 189
TABLE 121 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 190
TABLE 122 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 190
TABLE 123 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 191
TABLE 124 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 192
11.4.3 CHINA 192
11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period 192
TABLE 125 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 193
TABLE 126 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 194
TABLE 127 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 194
TABLE 128 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 195
TABLE 129 CHINA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 196
11.4.4 INDIA 196
11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market 196
TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 197
TABLE 131 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 198
TABLE 132 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 198
TABLE 133 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 199
TABLE 134 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 200
11.4.5 SOUTH KOREA 200
11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market 200
TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 201
TABLE 136 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 201
TABLE 137 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 202
TABLE 138 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203
TABLE 139 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 204
11.4.6 REST OF ASIA PACIFIC 204
TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 205
TABLE 141 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 206
TABLE 142 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 206
TABLE 143 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 207
TABLE 144 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 208
11.5 REST OF THE WORLD 208
TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION) 208
TABLE 146 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 209
TABLE 147 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 209
TABLE 148 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 210
TABLE 149 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 211
TABLE 150 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 212
11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD 212
11.5.2 LATIN AMERICA 212
11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market 212
TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 213
TABLE 152 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 214
TABLE 153 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 214
TABLE 154 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 215
TABLE 155 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 216
11.5.3 MIDDLE EAST & AFRICA 216
11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market 216
TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 217
TABLE 157 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 217
TABLE 158 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION) 218
TABLE 159 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 219
TABLE 160 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER, 2021–2028 (USD MILLION) 220
12 COMPETITIVE LANDSCAPE 221
12.1 OVERVIEW 221
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 221
TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS 222
12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 223
FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET 223
12.4 MARKET SHARE ANALYSIS 224
TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DEGREE OF COMPETITION 224
FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY MARKET SHARE, BY KEY PLAYER (2022) 225
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 226
12.5.1 STARS 226
12.5.2 EMERGING LEADERS 226
12.5.3 PERVASIVE PLAYERS 226
12.5.4 PARTICIPANTS 226
FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS 227
12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 228
12.6.1 PROGRESSIVE COMPANIES 228
12.6.2 STARTING BLOCKS 228
12.6.3 RESPONSIVE COMPANIES 228
12.6.4 DYNAMIC COMPANIES 228
FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES 229
12.7 COMPETITIVE BENCHMARKING 230
TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES 230
12.8 COMPANY FOOTPRINT ANALYSIS 231
TABLE 164 OVERALL COMPANY FOOTPRINT 231
TABLE 165 COMPANY PRODUCT FOOTPRINT 231
TABLE 166 COMPANY REGIONAL FOOTPRINT 232
12.9 COMPETITIVE SCENARIO 232
12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS 232
TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023 232
12.9.2 KEY DEALS 234
TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY MARKET: KEY DEALS, 2020–2023 234
12.9.3 OTHER KEY DEVELOPMENTS 234
TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020–2023 234

13 COMPANY PROFILES 236
13.1 KEY PLAYERS 236
(Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)*
13.1.1 F. HOFFMANN-LA ROCHE LTD. 236
TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 236
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 237
13.1.2 DANAHER CORPORATION 239
TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW 239
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 240
13.1.3 SIEMENS HEALTHINEERS AG 242
TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 242
FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 243
13.1.4 DIASORIN S.P.A. 246
TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW 246
FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) 247
13.1.5 ABBOTT LABORATORIES 248
TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW 248
FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 249
13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 251
TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 251
FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021) 252
13.1.7 SYSMEX CORPORATION 254
TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW 254
FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022) 255
13.1.8 DIATRON 258
TABLE 177 DIATRON: COMPANY OVERVIEW 258
FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022) 259
13.1.9 GETEIN BIOTECH, INC. 260
TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW 260
13.1.10 WERFEN 261
TABLE 179 WERFEN: COMPANY OVERVIEW 261
13.1.11 QUIDELORTHO CORPORATION 262
TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 262
FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 263
13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 265
TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW 265
*Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 267
13.2.1 MERCK KGAA 267
13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE) 267
13.2.3 TRIVITRON HEALTHCARE 268
13.2.4 ABNOVA CORPORATION 268
13.2.5 ELABSCIENCE 269
13.2.6 MACCURA BIOTECHNOLOGY CO., LTD. 269
13.2.7 AUTOBIO DIAGNOSTICS CO., LTD 270
13.2.8 JIANGSU ZECEN BIOTECH CO., LTD 270
13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD. 271
13.2.10 DAAN GENE CO., LTD. 272
13.2.11 DYNEX TECHNOLOGIES, INC. 272
13.2.12 ZYBIO INC. 273
13.2.13 WIENER LABORATORIOS SAIC 273
13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD. 274
14 APPENDIX 275
14.1 DISCUSSION GUIDE 275
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 279
14.3 CUSTOMIZATION OPTIONS 281
14.4 RELATED REPORTS 282
14.5 AUTHOR DETAILS 283

ページTOPに戻る

Table of Contents

Summary

The chemiluminescence immunoassay market is valued at an estimated USD 13.2 billion in 2023 and is projected to reach USD 19.0 billion by 2028 at a CAGR of 7.5% during the forecast period. Diseases such as HIV/AIDS, hepatitis, respiratory infections and sexually transmitted infections, require an accurate and timely diagnosis for effective treatment and control. Chemiluminescence immunoassay plays a major role in the diagnosis and monitoring of these infectious diseases, driving the growth of the market in this area.

“Blood samples segment is projected to witness highest growth rate in the chemiluminescence immunoassay market, by sample type, during the forecast period”
The chemiluminescence immunoassay market is segmented into blood, urine, saliva, and other sample types. The blood segment in chemiluminescence immunoassay is experiencing significant growth, primarily driven by the increasing number of blood donations and the rising incidence of chronic and infectious diseases also support the growth of the blood samples segment. According to the WHO, in 2020, over 118.5 million blood donations were collected worldwide. The WHO recommends testing all donated blood for infections before use, especially syphilis, HIV, malaria, HBV, and hepatitis B and C.
“Oncology testing segment is projected to register highest growth rate in the chemiluminescence immunoassay market, by application, during the forecast period”
The global chemiluminescence immunoassay market is bifurcated into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications. Oncology testing segment is expected to grow at the highest rate within the chemiluminescence immunoassay market. The surge in demand for oncology testing is attributed to various factors such as rise in the incidence of cancer, increasing emphasis on the need for early detection and treatment of cancer, along with measures to increase cancer screening measures.
“Asia Pacific: The fastest-growing region chemiluminescence immunoassay market”
The global chemiluminescence immunoassay market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in Asia Pacific such as China and India have been investing in developing their healthcare infrastructure, coupled with the presence of large target population. These factors are expected to provide significant growth opportunities for chemiluminescence immunoassay companies operating in this region.

The break-up of the profile of primary participants in the chemiluminescence immunoassay market:

• By Company Type: Tier 1 - 28%, Tier 2 - 41%, and Tier 3 – 31%
• By Designation: C-level - 30%, D-level - 34%, and Others - 36%
• By Region: North America - 37%, Europe - 28%, Asia Pacific - 20%, Rest of the World- 15%
The key players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Siemens Healthineers AG (Germany), DiaSorin S.p.A. (Italy), Abbott Laboratories (US), Shenzhen Mindray Bio-medical Electronics Co., Ltd. (China), Sysmex Corporation (Japan), Diatron (Hungary), Getein Biotech, Inc. (China), Werfen (Spain), QuidelOrtho Corporation (US), EUROIMMUN (Germany), Merck KGaA (Germany), Tosoh Corporation (Japan), Trivitron Healthcare (India), Abnova Corporation (Taiwan), Elabscience (US), Maccura Biotechnology Co., Ltd. (China), Autobio Diagnostics Co., Ltd. (China), Jiangsu Zecen Biotech Co., Ltd (China), Rayto Life and Analytical Sciences Co., Ltd. (China), Daan Gene Co., Ltd. (China), DYNEX TECHNOLOGIES, Inc. (US), Zybio, Inc. (China), Wiener Laboratorios SAIC (Argentina), Tianjin Era Biology Technology Co., Ltd. (China).
Research Coverage:
This research report categorizes the chemiluminescence immunoassay market by product (consumables and instruments), technology (Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence immunoassay (ECLI), and Microparticle Chemiluminescence Immunoassay), sample type (blood, urine, saliva, and other sample types), application (infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, therapeutic drug monitoring, respiratory, neurology, metabolic disorders, gastroenterology, and other applications), end user (hospitals, clinical laboratories, pharmaceuticals & biotechnology companies and contract research organizations, and other end users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the chemiluminescence immunoassay market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; acquisitions, agreements. new product launches and approvals, and recent developments associated with the chemiluminescence immunoassay market. Competitive analysis of upcoming startups in the chemiluminescence immunoassay market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall chemiluminescence immunoassay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (increasing incidences of chronic and infectious diseases, advances in improving the CLIA technologies, rising demand for point-of-care testing (POCT), growth of biotechnology and biopharmaceutical industries, growing geriatric population, and shift towards personalized medicine), restraints (high cost of CLIA systems and reagents and cross-reactivity and interference), opportunities (high growth prospects in emerging countries and collaborations and partnerships), and challenges (unfavorable reimbursement scenario and lack of skilled professionals) influencing the growth of the chemiluminescence immunoassay market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the chemiluminescence immunoassay market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the chemiluminescence immunoassay market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the chemiluminescence immunoassay market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Seimens Healthineers AG (Germany), Abbott Laboratories (US), and DiaSorin S.p.A.(Italy), among others in the chemiluminescence immunoassay market strategies.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（blood）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

化学発光免疫測定法市場：製品別（装置、消耗品）、技術別（化学発光酵素、微粒子化学発光）、サンプル別（血液、尿）、用途別（感染症、癌）、エンドユーザー別 - 2028年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（blood）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?